Introduction of a Quadrivalent Influenza Vaccine in Italy: a Budget Impact Analysis




In Italy the MoH offer for free, every year, influenza vaccination to all subjects at risk and to all subjects aged ≥ 65 year old.

Since the last flu season, TIVs were the only strategy used in Italy.

Traditional TIVs contain antigens from three viral strains: A(H1N1), A(H3N2), and one of two B lineages, B(Victoria) or B(Yamagata). Each year, the World Health Organization (WHO) decides which viral strains should be included in the next seasonal influenza vaccine.

However, accurately predicting which B-lineage strain will predominate in the upcoming season has proven to be a challenging task due to the co-circulation of both lineages.

To address the issue of B-mismatch, it’s been developed a new QIV containing both strains from each B-lineage to offer a broader protection against influenza.

The new QIV was reimbursed in Italy in 2015and included by the MoH in the national recommendations for the seasonal immunization campaign against influenza 2015-2016.

Recently a Health Technology Assessment (HTA) Report showed that the new QIV when compared to TIVs is cost effective (ICER=18.883€/QALY) according to Italian NHS perspective.

The Budget Impact Analysis (BIA) showed that the introduction of the QIV with 9% market share in the vaccine mix for the flu campaign 2015-2016 provides an annual saving of -674.089 €, mainly due to the wider protection offered by QIV vs TIVs with an estimated 49,12% B-mismatch.


Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 2012 Jan;8(1):81-88. Available from: PubMed PMID: 22252006. doi: 10.4161/hv.8.1.17623. [Google Scholar]

Skowronski DM, Masaro C, Kwindt TL, Mak A, Petric M, Li Y, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada.. Vaccine 2007;25(15):2842-2851. Available from: PubMed PMID: 17081662. doi: 10.1016/j.vaccine.2006.10.002. [Google Scholar]

Beran J, Wertzova V, Honegr K, Kaliskova E, Havlickova M, Havlik J, et al. Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis 2009;9(1):2-1186. Available from: PubMed PMID: 19149900. doi: 10.1186/1471-2334-9-2. [Google Scholar]

Skowronski DM, De Serres G, Dickinson J, Petric M, Mak A, Fonseca K, et al. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.. J Infect Dis 2009 Jan;199(2):168-179. Available from: PubMed PMID: 19086914. doi: 10.1086/595862. [Google Scholar]

Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, et al. Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.. Clin Infect Dis 2010;51(9):997-1004. Available from: PubMed PMID: 20868284. doi: 10.1086/656578. [Google Scholar]

Belongia EA, Kieke BA, Donahue JG, Coleman LA, Irving SA, Meece JK, et al. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results.. Vaccine 2011;29(38):6558-6563. Available from: PubMed PMID: 21767593. doi: 10.1016/j.vaccine.2011.07.002. [Google Scholar]

Heinonen S, Silvennoinen H, Lehtinen P, Vainionpää R, Ziegler T, Heikkinen T. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis 2011;11(1):23-29. Available from: PubMed PMID: 21106443. doi: 10.1016/S1473-3099(10)70255-3. [Google Scholar]

Janjua NZ, Skowronski DM, De Serres G, Dickinson J, Crowcroft NS, Taylor M, et al. Estimates of influenza vaccine effectiveness for 2007-2008 from Canada's sentinel surveillance system: cross-protection against major and minor variants.. J Infect Dis 2012 Apr;205(12):1858-1868. Available from: PubMed PMID: 22492921. doi: 10.1093/infdis/jis283. [Google Scholar]

Gazzetta Ufficiale Numero Determina 364/2015

Prevenzione e controllo dell’influenza: raccomandazioni per la stagione 2015-2016. Ministero della Salute Direzione Generale Della Prevenzione Sanitaria – CCM Ufficio V ex DGPREV - Malattie Infettive e Profilassi Internazionale

Barbieri M, Silvestri R,Boccalini S, de Waure C. Analisi di costo-efficacia della vaccinazione anti-influenzale in Italia. QIJPH 2015; Vol 4; N° 5 (6);70-83

National demographic institute. Istat.

Ryan J, Zoellner Y, Gradl B, Palache B, Medema J. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.. . Available from: PubMed PMID: 17034909. [Google Scholar]

Vaccinazione Antinfluenzale: stagione 2013/2014. Elaborazione MinSal –ISS aggiornamento 10/06/2914

Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.. . Available from: PubMed PMID: 14609480. [Google Scholar]

Tricco AC, Chit A, Soobiah C, Hallett D, Meier G, Chen MH, et al. Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis.. . Available from: PubMed PMID: 23800265. [Google Scholar]

incidence, e.a.T. (Sessa) , Italy, h.a.a.o.o.i.l.i.a.c.i.i. (natural) . . 2001;18:629-634. [Google Scholar]

Esposito S, Cantarutti L, Molteni CG, Daleno C, Scala A, Tagliabue C, et al. Clinical manifestations and socio-economic impact of influenza among healthy children in the community. Journal of Infection 2011;62(5):379-387. Available from: PubMed PMID: 21414357. doi: 10.1016/j.jinf.2011.02.015. [Google Scholar]